Zobrazeno 1 - 10
of 385
pro vyhledávání: '"BA Teicher"'
Publikováno v:
Science (New York, N.Y.). 247(4949 Pt 1)
EMT-6 murine mammary tumors were made resistant to cis-diamminedichloroplatinum (II) (CDDP), carboplatin, cyclophosphamide (CTX), or thiotepa in vivo by treatment of tumor-bearing animals with the drug during a 6-month period. In spite of high levels
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d035127b79abaf9ae971851b7a32690a
https://pubmed.ncbi.nlm.nih.gov/2108497
https://pubmed.ncbi.nlm.nih.gov/2108497
Autor:
Ba, Teicher, David Waxman, Sa, Holden, Yy, Wang, Clarke L, Alvarez Sotomayor E, Sm, Jones, Frei E
Publikováno v:
Europe PubMed Central
The cytotoxicity of N,N',N''-triethylenethiophosphoramide (thiotepa) was studied in vitro in the MCF-7 human breast carcinoma cell line and in vivo using the EMT6 mouse mammary tumor model, under various conditions of oxygenation and in the presence
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::fa64515a1198ac53b83a4b456d7d65d2
https://pubmed.ncbi.nlm.nih.gov/2504483
https://pubmed.ncbi.nlm.nih.gov/2504483
Publikováno v:
British Journal of Cancer
The SCC-25 cell line is a well-established line derived from a human squamous carcinoma of the head and neck. The capacity of this cell line for recovery from potentially lethal damage following X-ray treatment has been documented. The survival curve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7009c6caa264e60ee9a42f41a41e0ae
https://pubmed.ncbi.nlm.nih.gov/2436643
https://pubmed.ncbi.nlm.nih.gov/2436643
Autor:
Smith MA; National Cancer Institute, Bethesda, MD, United States of America. Electronic address: Malcolm.Smith@nih.gov., Houghton PJ; The University of Texas Health at San Antonio, TX, United States of America., Lock RB; Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, UNSW Medicine & Health, UNSW Centre for Childhood Cancer Research, UNSW Sydney, Sydney, NSW, Australia., Maris JM; The Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States of America., Gorlick R; The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America., Kurmasheva RT; The University of Texas Health at San Antonio, TX, United States of America., Li XN; Lurie Children's Hospital, Northwestern University Feiberg School of Medicine, Chicago, IL, United States of America., Teicher BA; National Cancer Institute, Bethesda, MD, United States of America., Chuang JH; The Jackson Laboratory for Genomic Medicine, Farmington, CT, United States of America., Dela Cruz FS; Memorial Sloan Kettering Cancer Center, New York City, NY, United States of America., Dyer MA; St. Jude Children's Research Hospital, Memphis, TN, United States of America., Kung AL; Memorial Sloan Kettering Cancer Center, New York City, NY, United States of America., Lloyd MW; The Jackson Laboratory for Mammalian Genetics, Bar Harbor, ME, United States of America., Mossé YP; The Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States of America., Stearns TM; The Jackson Laboratory for Mammalian Genetics, Bar Harbor, ME, United States of America., Stewart EA; St. Jude Children's Research Hospital, Memphis, TN, United States of America., Bult CJ; The Jackson Laboratory for Mammalian Genetics, Bar Harbor, ME, United States of America., Erickson SW; RTI International, Research Triangle Park, NC, United States of America.
Publikováno v:
Pharmacology & therapeutics [Pharmacol Ther] 2024 Dec; Vol. 264, pp. 108742. Date of Electronic Publication: 2024 Nov 05.
Autor:
Dexheimer TS; Target Validation and Screening Laboratory, Molecular Pharmacology Laboratory, Applied and Developmental Research Directorate, Frederick National Laboratory for Cancer Research, 1050 Boyles Street, Frederick, MD 21702, USA. Electronic address: thomas.dexheimer@nih.gov., Coussens NP; Target Validation and Screening Laboratory, Molecular Pharmacology Laboratory, Applied and Developmental Research Directorate, Frederick National Laboratory for Cancer Research, 1050 Boyles Street, Frederick, MD 21702, USA., Silvers T; Target Validation and Screening Laboratory, Molecular Pharmacology Laboratory, Applied and Developmental Research Directorate, Frederick National Laboratory for Cancer Research, 1050 Boyles Street, Frederick, MD 21702, USA., Jones EM; Target Validation and Screening Laboratory, Molecular Pharmacology Laboratory, Applied and Developmental Research Directorate, Frederick National Laboratory for Cancer Research, 1050 Boyles Street, Frederick, MD 21702, USA., Chen L; Molecular Characterization Laboratory, Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA., Fang J; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA., Morris J; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA., Moscow JA; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA., Doroshow JH; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA., Teicher BA; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Publikováno v:
SLAS discovery : advancing life sciences R & D [SLAS Discov] 2024 Oct; Vol. 29 (7), pp. 100186. Date of Electronic Publication: 2024 Oct 01.
Autor:
Sonkin D; National Cancer Institute, Division of Cancer Treatment and Diagnosis, Rockville, MD 20850, USA. Electronic address: dmitriy.sonkin@nih.gov., Thomas A; National Cancer Institute, Center for Cancer Research, Bethesda, MD 20892, USA., Teicher BA; National Cancer Institute, Division of Cancer Treatment and Diagnosis, Rockville, MD 20850, USA.
Publikováno v:
Cancer genetics [Cancer Genet] 2024 Aug; Vol. 286-287, pp. 18-24. Date of Electronic Publication: 2024 Jun 17.
Autor:
Kunkel MW; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Coussens NP; Molecular Pharmacology Laboratories, Applied and Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Morris J; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Taylor RC; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Dexheimer TS; Molecular Pharmacology Laboratories, Applied and Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Jones EM; Molecular Pharmacology Laboratories, Applied and Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Doroshow JH; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Teicher BA; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.
Publikováno v:
Cancer research [Cancer Res] 2024 Aug 01; Vol. 84 (15), pp. 2403-2416.
Autor:
Randall J; Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, University of New South Wales Medicine & Health, Centre for Childhood Cancer Research, University of New South Wales Sydney, Sydney, NSW, Australia., Evans K; Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, University of New South Wales Medicine & Health, Centre for Childhood Cancer Research, University of New South Wales Sydney, Sydney, NSW, Australia., Watts B; Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, University of New South Wales Medicine & Health, Centre for Childhood Cancer Research, University of New South Wales Sydney, Sydney, NSW, Australia., Kosasih HJ; Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, University of New South Wales Medicine & Health, Centre for Childhood Cancer Research, University of New South Wales Sydney, Sydney, NSW, Australia., Smith CM; Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, University of New South Wales Medicine & Health, Centre for Childhood Cancer Research, University of New South Wales Sydney, Sydney, NSW, Australia., Earley EJ; RTI International, Research Triangle Park, Research Triangle, NC., Erickson SW; RTI International, Research Triangle Park, Research Triangle, NC., Jocoy EL; The Jackson Laboratory, Sacramento, CA., Bult CJ; The Jackson Laboratory, Bar Harbor, ME., Teicher BA; National Cancer Institute, Bethesda, MD., de Bock CE; Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, University of New South Wales Medicine & Health, Centre for Childhood Cancer Research, University of New South Wales Sydney, Sydney, NSW, Australia., Smith MA; National Cancer Institute, Bethesda, MD., Lock RB; Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, University of New South Wales Medicine & Health, Centre for Childhood Cancer Research, University of New South Wales Sydney, Sydney, NSW, Australia. Electronic address: rlock@ccia.org.au.
Publikováno v:
Experimental hematology [Exp Hematol] 2024 Apr; Vol. 132, pp. 104176. Date of Electronic Publication: 2024 Feb 05.
Autor:
Morris J; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland., Kunkel MW; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland., White SL; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland., Wishka DG; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland., Lopez OD; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland., Bowles L; Target Validation and Screening Laboratory, Applied and Developmental Research Directorate, Frederick National, Laboratory for Cancer Research, Frederick, Maryland., Sellers Brady P; Target Validation and Screening Laboratory, Applied and Developmental Research Directorate, Frederick National, Laboratory for Cancer Research, Frederick, Maryland., Ramsey P; Target Validation and Screening Laboratory, Applied and Developmental Research Directorate, Frederick National, Laboratory for Cancer Research, Frederick, Maryland., Grams J; Target Validation and Screening Laboratory, Applied and Developmental Research Directorate, Frederick National, Laboratory for Cancer Research, Frederick, Maryland., Rohrer T; Target Validation and Screening Laboratory, Applied and Developmental Research Directorate, Frederick National, Laboratory for Cancer Research, Frederick, Maryland., Martin K; Target Validation and Screening Laboratory, Applied and Developmental Research Directorate, Frederick National, Laboratory for Cancer Research, Frederick, Maryland., Dexheimer TS; Target Validation and Screening Laboratory, Applied and Developmental Research Directorate, Frederick National, Laboratory for Cancer Research, Frederick, Maryland., Coussens NP; Target Validation and Screening Laboratory, Applied and Developmental Research Directorate, Frederick National, Laboratory for Cancer Research, Frederick, Maryland., Evans D; Target Validation and Screening Laboratory, Applied and Developmental Research Directorate, Frederick National, Laboratory for Cancer Research, Frederick, Maryland., Risbood P; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland., Sonkin D; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland., Williams JD; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland., Polley EC; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland., Collins JM; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland., Doroshow JH; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland., Teicher BA; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland.
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2023 Nov 01; Vol. 22 (11), pp. 1270-1279.
Autor:
Dexheimer TS; Molecular Pharmacology Laboratories, Applied and Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Coussens NP; Molecular Pharmacology Laboratories, Applied and Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Silvers T; Molecular Pharmacology Laboratories, Applied and Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Wright J; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland., Morris J; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland., Doroshow JH; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland., Teicher BA; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland.
Publikováno v:
Cancer research communications [Cancer Res Commun] 2023 Aug 25; Vol. 3 (8), pp. 1648-1661. Date of Electronic Publication: 2023 Aug 25 (Print Publication: 2023).